Tango Therapeutics Inc. (TNGX)
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 10:19 AM ET
TNGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.59B
- EPS (TTM)
- -$0.85
- Dividend yield
- None
- 52-week range
- 6.69 – 34.39
- Day range
- 21.29 – 21.82
- Volume / Avg
- 219.42K / 2.61M
- Beta
- —
- Shares outstanding
- 168.61M
- Next earnings
- Nov 3, 2026
52-week range
TNGX stock today
Tango Therapeutics (TNGX) is trading at $21.31 on Oct 8, down 2.38% (-$0.52), versus the S&P 500's 0.19% decline. Shares are 38.0% below their 52-week high of $34.39, set on Jun 17, 2026 and 218.5% above the 52-week low of $6.69, in the middle of the past year's range. TNGX is up 146.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 199.5%.
Tango Therapeutics has posted a net loss over the last twelve months (EPS of -$0.85), so its P/E ratio is not meaningful. Tango Therapeutics's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Tango Therapeutics
Company profileTango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Malte Peters M.D.
- Headquarters
- Boston, MA
- Employees
- 137
- IPO year
- 2020
- Website
- tangotx.com
Financial highlights
Full financialsIn fiscal 2025, Tango Therapeutics generated $62.4 million in revenue, up 48.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Tango Therapeutics reported a net loss of $101.6 million, compared with a loss of $130.3 million a year earlier. Operating margin was -178.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $62.38M | $42.07M | $36.53M | $24.86M | $37.04M |
| Growth | +48.29% | +15.17% | +46.93% | -32.89% | +383.83% |
| Net income | $-101.59M | $-130.30M | $-101.74M | $-108.18M | $-58.23M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$45.18+112.01%
- Strong buy 1
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.34
- Last reported (Q2 2026)
- Aug 11, 2026
- EPS actual vs est.
- $-0.37 vs —
TNGX news
All TNGX newsTango Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited ADR | 11.00 | -1.08% | $3.74B | vs TNGX |
| OGNOrganon & Co. | 13.79 | -0.04% | $3.62B | vs TNGX |
| LEGNLegend Biotech Corporation ADR | 18.28 | -4.42% | $3.55B | vs TNGX |
| VKTXViking Therapeutics Inc. | 27.53 | -3.54% | $3.50B | vs TNGX |
| ABCLAbCellera Biologics Inc. | 12.10 | -5.73% | $3.92B | vs TNGX |
| XENEXenon Pharmaceuticals Inc. | 35.64 | -2.11% | $3.45B | vs TNGX |
| IDYAIDEAYA Biosciences Inc. | 35.18 | -2.98% | $3.39B | vs TNGX |
| ACADACADIA Pharmaceuticals Inc. | 19.47 | -0.92% | $3.35B | vs TNGX |
Indexes, lists and sector
Tango Therapeutics stock FAQ
What is Tango Therapeutics's stock price today?
TNGX last traded at $21.31 as of Oct 8, 10:19 AM EDT, down 2.38% on the day. Prices are delayed at least 15 minutes.
When is Tango Therapeutics's next earnings date?
Tango Therapeutics is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.34.
Who is Tango Therapeutics's CEO?
Dr. Malte Peters M.D. is the chief executive officer of Tango Therapeutics Inc., which has about 137 employees.
What is the TNGX 52-week high?
The 52-week high for TNGX is $34.39 and the 52-week low is $6.69. The stock is currently 38.0% below its high.